Module 9 2021

22/03/2021

Immune responses to a biotherapeutic

Biotherapeutic in Patient

non immunogenic (e.g., GCSF, IFN g )

no effect (e.g., insulin, growth hormone)

immunogenic (induced antibodies - ADA )

alter PK / PD

neutralise biological effects and compromise further therapy (e.g., factor VIII, IFN a 2a, GM-CSF)

Cross-react with native protein and induce adverse symptoms (e.g., Epo, MGDF)

Infusion reactions, anaphylactic reactions Delayed-type hypersensitivity

Consequences on efficacy - reduction or loss of clinical response to the biotherapeutic Consequences on safety - safety issues can occur even when there is no loss of efficacy

The Organisation for Professionals in Regulatory Affairs

7

Immunogenicity of biotherapeutics: examples

Antibody Product name®

Indication

Type of antibody

% ADA +ve patients

OKT3

Allograft rejection

Murine

25

Bexxar

Non-Hodgkins lymphoma

Murine

11

Remicade

Crohn’s Disease & RA

Chimeric

10 - 60

Simulect

Transplant rejection

Chimeric

1 - 2

Rituxan

Non-Hodgkins lymphoma

Chimeric

11

Raptiva

Psoriasis

Humanized

6.3

CAMPATH

Leukemia

Humanized

50

Herceptin

Cancer

Humanized

<1

Humira

Crohn’s Disease, AS, RA

Fully-human

2.6 - 89

Vectibix

Colorectal cancer

Fully-human

4.6

The Organisation for Professionals in Regulatory Affairs

8

4